Hospital

With rapid growth, health system specialty pharmacies are more than likely to run into several operational pain points.

With specialty pharmacy emerging as the fastest growing segment of the pharmacy industry, health systems have to address a key question: can you scale for it?

Acetaminophen-related overdose continues to be a leading cause of emergency deparment visits and hospitalizations and remains the leading cause of drug-induced acute liver failure in the United States.

Community Pharmacy Consultant Bruce Kneeland and Kevin DeMass, RPh, President of Apothecary Shoppe, Salt Lake City, UT, discuss how pharmacy works with hospitals to improve outcomes for patients.

The Neostigmine Methylsulfate Injection is the first manufacturer-prepared, ready-to-administer prefilled syringe on the market.

Ali McBride, PharmD, MS, BCPS, BCOP, explains what strategies can help ensure patients are adherent to oral chemotherapy regimens.

Nancy Egerton, PharmD, BCOP, discusses the pharmacist's role in oncology care.

Three female leaders in pharmacy discuss the changes in this industry.

Julianne Orr, PharmD, discusses how pharmacists can help patients transitioning from infusion chemotherapy products to oral agents.

Over the years, a number of landmark clinical studies on the management of AF have been published, sharping how patients are treated. Here are 4 that every pharmacist should know about.

The combination of nivolumab (Opdivo) and ipilimumab (Yervoy) improved progression-free survival (PFS) compared with chemotherapy in treatment-naïve patients with high tumor mutation burden (TMB) non–small cell lung cancer (NSCLC).

The Institute for Safe Medication Practices recently added new best practices for improving patient safety in hospitals.

Pharmacists are the crux of successful care transitions between hospitals and post-acute care facilities.

Black children with severe pain are less likely to receive opioids in emergency rooms than white children.

The placebo effect is growing stronger in US clinical trials for chronic pain medications.

Citing a rare yet serious risk of slowed breathing, the FDA is evaluating the use of the opioid pain medication tramadol (Ultram, Ultram ER, Conzip) in the pediatric population.

Pregabalin and gabapentin are often considered first-line treatments for various neuropathic pain syndromes, generally irrespective of cause.